KRAS G12C-mutant non-small cell lung cancer: A practical guide for clinicians

Cancer Treatment Reviews · Published 2026-05-06 · DOI 10.1016/j.ctrv.2026.103144

Authors being retrieved — see the publisher record. https://doi.org/10.1016/j.ctrv.2026.103144

Abstract

PubPorta does not have an abstract for this article yet.

Read the article at the publisher →

Publication details

Year

2026

Related articles

• Targeting key epigenetic regulators in solid tumors: focus on EZH2, PRMT5, and BET inhibitors · Cancer Treatment Reviews · 2026 · Same journal
• Glioblastoma and resistance to radiotherapy: role of cancer stem cells subpopulations, hypoxia and therapeutic strategies · Cancer Treatment Reviews · 2026 · Same journal
• Pharmacological prevention of second primary cancers: From chemoprevention to precision cancer interception · Cancer Treatment Reviews · 2026 · Same journal
• Circulating tumor DNA in breast cancer: From technological foundation to clinical implementation · Cancer Treatment Reviews · 2026 · Same journal
• Multigene assays in early breast cancer: Current evidence, limits and future directions · Cancer Treatment Reviews · 2026 · Same journal
• Cyclotherapy: exploiting cell-cycle decoupling for selective cancer cytotoxicity and normal-tissue protection · Cancer Treatment Reviews · 2026 · Same journal
• Cellular senescence: A novel mechanism of therapeutic resistance in prostate cancer · Cancer Treatment Reviews · 2025 · Same journal
• Is Cytoreductive surgery for unresectable colorectal liver metastases able to improve patient outcome? Results of a pilot prospective study · Cancer Treatment Reviews · 2026 · Same journal
• Targeting HER2 in urothelial carcinoma: from pathway inhibition to antibody–drug conjugates · Cancer Treatment Reviews · 2026 · Same journal
• Biomarker-guided immunotherapy in gastric cancer: current insights and future perspectives · Cancer Treatment Reviews · 2026 · Same journal